Nikolaeva Marina A, Babayan Alina A, Stepanova Elena O, Smolnikova Veronika Y, Kalinina Elena A, Fernández Nelson, Krechetova Lubov V, Vanko Ludmila V, Sukhikh Gennady T
Laboratory of Clinical Immunology, The Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology" of the Ministry of Healthcare of the Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
Laboratory of Clinical Immunology, The Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology" of the Ministry of Healthcare of the Russian Federation, Oparina Str. 4, 117997 Moscow, Russia.
J Reprod Immunol. 2016 Sep;117:45-51. doi: 10.1016/j.jri.2016.03.006. Epub 2016 Jul 5.
It has been proposed that the transforming growth factor (TGF)-β1 present in seminal plasma (SP) triggers a female immune response favorable for implantation. We hypothesize that seminal interleukin (IL)-18, a cytokine that can potentially cause implantation failure, interferes with the beneficial effect of TGF-β1. This study aims to determine whether the levels of seminal TGF-β1 and IL-18 are associated with reproductive outcomes in patients exposed to SP during in vitro fertilization (IVF) or IVF with intracytoplasmic sperm injection (ICSI). A prospective study, which included 71 couples undergoing IVF/ICSI was carried out. Female patients were exposed to their partners' SP via timed intercourse before the day of ovum pick-up (OPU) and also subjected to intravaginal SP application just after OPU. Quantitative measurements of total TGF-β1 (active plus latent) as well as IL-18 were determined by FlowCytomix™ technology in the SP to be used for intravaginal applications. Comparison of SP cytokine profiles between pregnant and non-pregnant groups revealed that pregnancy was correlated with a lower concentration of IL-18 (P=0.018) and lower content per ejaculate for both of IL-18 (P=0.0003) and TGF-β1 (P=0.047). The ratio of TGF-β1-to-IL-18 concentration was significantly higher in the pregnant than in the non-pregnant group (P=0.026). This study supports the notion that two key cytokines TGF-β1 and IL-18, both present in SP are associated with reproductive outcomes in female patients exposed to SP during IVF/ICSI treatment.
有人提出，精浆（SP）中存在的转化生长因子（TGF）-β1会引发有利于着床的女性免疫反应。我们推测，精浆白细胞介素（IL）-18这种可能导致着床失败的细胞因子，会干扰TGF-β1的有益作用。本研究旨在确定在体外受精（IVF）或卵胞浆内单精子注射（ICSI）的IVF过程中接触精浆的患者，其精浆中TGF-β1和IL-18水平是否与生殖结局相关。进行了一项前瞻性研究，纳入了71对接受IVF/ICSI的夫妇。女性患者在取卵（OPU）日前通过定时性交接触伴侣的精浆，并在OPU后立即进行阴道内精浆应用。通过FlowCytomix™技术对用于阴道内应用的精浆中的总TGF-β1（活性加潜伏性）以及IL-18进行定量测量。怀孕组和未怀孕组精浆细胞因子谱的比较显示，怀孕与较低浓度的IL-18相关（P = 0.018），并且IL-18（P = 0.0003）和TGF-β1（P = 0.047）的每次射精含量均较低。怀孕组中TGF-β1与IL-18浓度的比值显著高于未怀孕组（P = 0.026）。本研究支持这样一种观点，即在IVF/ICSI治疗期间接触精浆的女性患者中，精浆中存在的两种关键细胞因子TGF-β1和IL-18与生殖结局相关。
